title: Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
abstract: Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
authors.affiliation: Department of Neurology and Center for Clinical Neuroscience, Charles University, General Hospital, Prague, Czech Republic. janaprei.lizr@gmail.com
authors.forename: Jana Lizrova
authors.initials: JL
authors.lastname: Preiningerova
authors.forename: Ulf
authors.initials: U
authors.lastname: Baumhackl
authors.forename: Tunde
authors.initials: T
authors.lastname: Csepany
authors.forename: Adam
authors.initials: A
authors.lastname: Czaplinski
authors.forename: Florian
authors.initials: F
authors.lastname: Deisenhammer
authors.forename: Tobias
authors.initials: T
authors.lastname: Derfuss
authors.forename: Tanja H
authors.initials: TH
authors.lastname: Fabjan
authors.forename: Franz
authors.initials: F
authors.lastname: Fazekas
authors.forename: Siegrid
authors.initials: S
authors.lastname: Fuchs
authors.forename: Eva
authors.initials: E
authors.lastname: Havrdova
authors.forename: Alenka Horvath
authors.initials: AH
authors.lastname: Ledinek
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Illes
authors.forename: Sasa Sega
authors.initials: SS
authors.lastname: Jazbec
authors.forename: Eleonora
authors.initials: E
authors.lastname: Klimova
authors.forename: Samuel
authors.initials: S
authors.lastname: Komoly
authors.forename: Egon
authors.initials: E
authors.lastname: Kurca
authors.forename: Michael
authors.initials: M
authors.lastname: Linnebank
authors.forename: Lubomir
authors.initials: L
authors.lastname: Lisy
authors.forename: Jan
authors.initials: J
authors.lastname: Mares
authors.forename: Lubica
authors.initials: L
authors.lastname: Prochazkova
authors.forename: Rozsa
authors.initials: R
authors.lastname: Csilla
authors.forename: Jarmila
authors.initials: J
authors.lastname: Szilasiova
authors.forename: Pavel
authors.initials: P
authors.lastname: Stourac
authors.forename: Radomir
authors.initials: R
authors.lastname: Talab
authors.forename: Peter
authors.initials: P
authors.lastname: Turcani
authors.forename: Marta
authors.initials: M
authors.lastname: Vachova
authors.forename: Laszlo
authors.initials: L
authors.lastname: Vecsei
authors.forename: David
authors.initials: D
authors.lastname: Vodusek
authors.forename: Olga
authors.initials: O
authors.lastname: Zapletalova
authors.forename: Thomas
authors.initials: T
authors.lastname: Berger
mesh_terms: D015761:4-Aminopyridine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine